Jpmorgan Chase & CO Karyopharm Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,385,724 shares of KPTI stock, worth $914,577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,385,724
Previous 1,275,859
8.61%
Holding current value
$914,577
Previous $1.11 Million
3.7%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding KPTI
# of Institutions
94Shares Held
56.5MCall Options Held
258KPut Options Held
81.2K-
Vanguard Group Inc Valley Forge, PA7.65MShares$5.05 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY5.55MShares$3.66 Million0.36% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$3.37 Million0.58% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$2.85 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$2.75 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $52.7M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...